- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Indian Hospital Industry saw private equity deals worth over Rs 27000 crore in last two years: ICRA
New Delhi: The Indian hospital industry is expected to remain strong in the coming year, with a projected aggregate occupancy rate of 63-65% and a growth in average revenue per occupied bed (ARPOB) of 5-7%, a recent report by rating agency ICRA has stated.
With this ICRA has maintained its Stable outlook on the Indian hospital industry noting that Operating profit margin will remain healthy at over 22% in FY2024, supported by operating leverage and continued benefits from cost optimisation measures.
While turnaround in operations of many of the new centres for some hospital companies improved the sample set return on capital employed (ROCE) to 18% in FY2022 (from 6% in FY2021), relatively higher capital expenditure moderated the same to 16% in FY2023. Going forward, the ROCE is expected to remain between 13-15% for the sample set, supported by incremental absolute OPBDITA, despite additional capital being deployed towards setting up new capacities.
Read also: Top domestic pharmaceutical firms revenue to grow by 7-9 percent in FY24: Icra
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751